Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany for the epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults;Epidemiologie, diagnostik, antimikrobielle therapie und management von erwachsenen patienten mit ambulant erworbenen tiefen atemwegsinfektionen (akute bronchitis, akute exazerbation einer chronischen bronchitis, influenza und andere respiratorische virus-infektionen) sowie ambulant erworbener pneumonie

Chemotherapie Journal

Volumn 14, Issue 4, 2005, Pages 97-155

  Höffken, Gert ^a,e,f   Lorenz, Joachim ^b   Kern, Werner ^c   Welte, Tobias ^d   Bauer, Torsten ^g   Dalhoff, Klaus ^g   Dietrich, Eva ^g   Ewig, Santiago ^g   Gastmeier, Petra ^g   Grabein, Beatrice ^g   Halle, Elke ^g   Kolditz, Martin ^g   Marre, Reinhard ^g   Sitter, Helmut ^g  

^a Paul Ehrlich Gesellschaft für Chemotherapie e V Federführend   (Germany)

^b Deutsche Gesellschaft für Pneumologie e V

^c Deutsche Gesellschaft für Infektiologie e V

^d Kompetenz Netzwerk CAPNETZ Deutschland e V

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f Fachkrankenhaus Coswig   (Germany)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DOXYCYCLINE; ERTAPENEM; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PENICILLIN G; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; SULTAMICILLIN; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BLOOD CULTURE; COMMUNICABLE DISEASE; DRUG INDICATION; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; INCIDENCE; LOWER RESPIRATORY TRACT INFECTION; MEDICAL SOCIETY; PATIENT CARE; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK; RISK ASSESSMENT; SYMPTOM; THORAX RADIOGRAPHY;

EID: 23944516312     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (428)

1. Abele-Horn M, Busch U, Nitschko H, et al. Molecular approaches to diagnosis of pulmonary diseases due to Mycoplasma pneumoniae. J Clin Microbiol 1998;36:548-551.
2. Adams SG, Melo J, Luther M, Anzueto A. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD. Chest 2000;117:1345-1352.
3. Ahkee S, Srinath L, Ramirez J. Community-acquired pneumonia in the elderly: association of mortality with lack of fever and leukocytosis. South Med J 1997;90:296-298.
4. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999;159:266-270.
5. Al Eidan FA, McElnay JC, Scott MG, Kearney MP, Corrigan J, McConnell JB. Use of a treatment protocol in the management of community-acquired lower respiratory tract infection. J Antimicrob Chemother 2000;45: 387-394.
6. Allewelt M, Schuler P, Bolcskei PL, Mauch H, Lode H. Ampicillin + sulbactam vs clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 2004;10:163-170.
7. Allewelt M, Steinhoff D, Rahlwes M, et al. Wandel im Erregerspektrum ambulant-erworbener Pneumonien (1982-1992). Dtsch Med Wochenschr 1997;122(34-35):1027-1032.
8. Almirall J, Bolibar I, Toran P, et al. Contribution of C-Reactive Protein to the Diagnosis and Assessment of Severity of Community-Acquired Pneumonia. Chest 2004;125:1335-1342.
9. Ambrose PG, Quintiliani R, Nightingale CH, Nicolau DP. Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infect Dis Clin Pract 1998;7:463-470.
10. American Thoracic Society. Hospital-acquired pneumonia in adults: Diagnosis, assessment, initial therapy, and prevention: A consensus statement. Am J Respir Crit Care Med 1996;153:1711-1725.
11. Anderson KB, Tan JS, File TM, Jr., DiPersio JR, Willey BM, Low DE. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-381.
12. Angrill J, Celis R, Arancibia F, et al. Bacterial colonization in patients with bronchiectasis: prevalence and comparison of diagnostic techniques. American Journal of Respiratory and Critical Care Medicine 159[3], A559. 1999. Ref Type: Abstract
13. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-723.
14. Anon JM, Garcia dL, Zarazaga A, Gomez-Tello V, Garrido G. Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease: prognosis and cost-utility analysis. Intensive Care Med 1999;25: 452-457.
15. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
16. Anzueto A, Niederman MS, Tillotson GS. Etiology, susceptibility, and treatment of acute bacterial exacerbations of complicated chronic bronchitis in the primary care setting: ciprofloxacin 750 mg b.i.d. versus clarithromycin 500 mg b.i.d. Bronchitis Study Group. Clin Ther 1998;20:885-900.
17. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired Pneumonia caused by Gram-negative bacteria: Incidence and risk and prognosis. Arch Intern Med 2002;162: 1849-1858.
18. Arancibia F, Bauer TT, Torres A, et al. Community-acquired Pneumonia caused by Gram-negative bacteria: Incidence and risk and prognosis. Eur Respir J 14(Suppl.30), 419s. 1999.
19. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: Causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-160.
20. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444.
21. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. QJM 1995;88:61-68.
22. Bandyopadhyay T, Gerardi DA, Metersky ML. A comparison of induced and expectorated sputum for the microbiological diagnosis of community acquired pneumonia. Respiration 2000;67:173-176.
23. Barker AF. Bronchiectasis. The New England Journal of Medicine 2002;346:1383-1393.
24. Bartlett JG, Breiman RF, Mandell LA, File TMJr. Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 1998;26:811-838.
25. Bartlett JG, Dowell SF, Mandell LA, File TMJr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:422-425.
26. Bartlett JG, Mundy LM. Community-Acquired Pneumonia. The New England Journal of Medicine 1995;333:1618-1624.
27. Bartlett JG. Empirical therapy of community-acquired pneumonia: macrolides are not ideal choices. Semin Respir Infect 1997;12: 329-333.
28. Baudouin SV. The pulmonary physician in critical care. 3: critical care management of community acquired pneumonia. Thorax 2002;57:267-271.
29. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. Prospective comparision of CURB, CRB, CRB-65 scores for predicting mortality in hospitalized patients and outpatients with CAP. in press. In press.
30. Beaty CD, Grayston JT, Wang SP, Kuo CC, Reto CS, Martin TR. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;144:1408-1410.
31. Beyer WE, de Bruijn IA, Palache AM, Westendorp RG, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999;159:182-188.
32. Beyer WE, Palache AM, de long JC, Osterhaus AD. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002;20(9-10):1340-1353.
33. Blasi F, Damato S, Cosentini R, et al. Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment. Thorax 2002;57: 672-676.
34. Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993;6:19-22.
35. Böhmer W, Loos U, Heissenberg A, Kullmann KH. Leitliniengesteuertes infektioloisches Qualitätsmanagement auf einer internistischen Allgemeinstation bei Patienten mit ambulant erworbener Pneumonie. Chemother J 2002;11:83-86.
36. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543-547.
37. Bohte R, van't Wout JW, Lobatto S, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995;14:182-187.
38. Boswell TC, Marshall LE, Kudesia G. False-positive legionella titres in routine clinical serology testing detected by absorption with campylobacter: implications for the serological diagnosis of legionnaires' disease. J Infect 1996;32:23-26.
39. British Thoracic Society and the Public Health Laboratory Service. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome. Q J Med 1987;62(239):195-200.
40. British Thoracic Society. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56(90004):1iv-64.
41. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made data-base. Chest 2003;123:1503-1511.
42. Buscho RO, Saxtan D, Shultz PS, Finch E, Mufson MA. Infections with viruses and Mycoplasma pneumoniae during exacerbations of chronic bronchitis. J Infect Dis 1978;137:377-383.
43. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The Contribution of Blood Cultures to the Clinical Management of Adult Patients Admitted to the Hospital With Community-Acquired Pneumonia: A Prospective Observational Study. Chest 2003;123:1142-1150.
44. Canton R, Morosini M, Enright MC, Morrissey I. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003;52:944-952.
45. Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004;39:955-963.
46. Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tolerated treatment for community-acquired pneumonia. Clin Microbiol Infect 2003;9:691-703.
47. Carson PJ, Nichol KL, O'Brien J, Hilo P, Janoff EN. Immune function and vaccine responses in healthy advanced elderly patients. Arch Intern Med 2000;160:2017-2024.
48. Castro-Guardiola A, Viejo-Rodriguez AL, Soler-Simon S, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001;111:367-374.
49. Center for Disease Control and Prevention. Introduction to Table V. Premature deaths, monthly mortality, and monthly physician contacts - United States. 46, 556-561. 1997. MMWR Morb Mortal Wkly Rep.
50. Chalasani NP, Valdecanas MA, Gopal AK, McGowan JE, Jr., Jurado RL. Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks. Chest 1995;108:932-936.
51. Chapman TM, Perry CM. Cefepime: a review of its use in the management of hospitalized patients with pneumonia. Am J Respir Med 2003;2:75-107.
52. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003;290:2588-2598.
53. Chien SM, Pichotta P, Siepman N, Chan CK. Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. Chest 1993;103: 697-701.
54. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:722-729.
55. Chodosh S, Schreurs A, Siami G, et al. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998;27:730-738.
56. Christ-Grain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363(9409):600-607.
57. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001;357(9261): 1008-1011.
58. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicllin-resistant and multidrug-resistant Streptococcus pneumoniae: A multicenter study. Clin Infect Dis 1997;24:1052-1059.
59. Cloud JL, Carroll KC, Pixton P, Erali M, Hillyard DR. Detection of Legionella species in respiratory specimens using PCR with sequencing confirmation. J Clin Microbiol 2000;38:1709-1712.
60. Coley KC. Changing physician prescribing behavior: The Community-Acquired Pneumonia Intervention Trial. Am J Health Syst Pharm 57[15], 1506-1510. 2000. Ref Type: Journal (Full)
61. Colice GL, Curtis A, Deslauriers J, et al. Medical and surgical treatment of parapneumonic effusions: an evidence-based guideline. Chest 2000;118:1158-1171.
62. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001;19:4780-4790.
63. Correa JC, Badaro R, Bumroongkit C, et al. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization. Clin Ther 2003;25:1453-1468.
64. Cosentini R, Blasi F, Raccanelli R, et al. Severe community-acquired pneumonia: a possible role for Chlamydia pneumoniae. Respiration 1996;63:61-65.
65. Dahmash NS, Chowdhury MN. Re-evaluation of pneumonia requiring admission to an intensive care unit: a prospective study. Thorax 1994;49:71-76.
66. Dalhoff K, Ewig S, Höffken G, et al. Empfehlungen zur Diagnostik, Therapie und Prävention von Pneumonien bei erworbenem Immundefizit. Pneumologie 2003;56:807-831.
67. Dansey RD, Jacka PJ, Strachan SA, Hay M. Comparison of cefotaxime with ceftriaxone given intramuscularly 12-hourly for community-acquired pneumonia. Diagn Microbiol Infect Dis 1992;15:81-84.
68. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-750.
69. de Klerk GJ, van Steijn JH, Lobatto S, et al. A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections. Int J Antimicrob Agents 1999;12:121-127.
70. de Roux A, Marcos MA, Garcia E, et al. Viral Community-Acquired Pneumonia in Nonimmunocompromised Adults. Chest 2004;125:1343-1351.
71. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001;110:451-457.
72. Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics 1999;103: 409-413.
73. Descheemaeker P, Chapelle S, Lammens C, et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother 2000;45:167-173.
74. Diehr P, Wood RW, Bushyhead J, Krueger L, Wolcott B, Tompkins RK. Prediction of pneumonia in outpatients with acute cough - a statistical approach. J Chronic Dis 1984;37: 215-225.
75. Dietrich ES, Brockmann S, Frank UWE, Daschner FD. The economic impact of unnecessary hospital admissions of patients with community acquired pneumonia. 15th Annual Meeting of the ISTAHC 1999.
76. Dietrich ES, Jopp R, Schreier U, Gilge R, Bartmann P. Kosten einer leitliniengerechten Arzneimitteltherapie in Deutschland. Gesundh ökon Qual manag 2005;10:35-43.
77. Dietrich ES, Joseph U, Vogel F, et al. Cost-effectiveness of ceftriaxone 1 g vs second-generation cephalosporins in the treatment of pneumonia in general medical wards in Germany. Infection 1999;27:148-154.
78. Dietrich ES, Schmid M, Bucher A, Lemmen SW. Kostenreduktion in der Antibiotika-Therapie. Krankenhauspharmazie 1998;19:287-292.
79. Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae Antigen by a Rapid Immunochromatographic Assay in Urine Samples. Chest 2001;119:243-249.
80. Dominguez JA, Matas L, Manterola JM, et al. Comparison of radioimmunoassay and enzyme immunoassay kits for detection of Legionella pneumophila serogroup 1 antigen in both concentrated and nonconcentrated urine samples. J Clin Microbiol 1997;35: 1627-1629.
81. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
82. Dorigo-Zetsma JW, Verkooyen RP, van Helden HP, van der NH, van den Bosch JM. Molecular detection of Mycoplasma pneumoniae in adults with community-acquired pneumonia requiring hospitalization. J Clin Microbiol 2001;39:1184-1186.
83. Dorigo-Zetsma JW, Zaat SA, et al. Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children. J Clin Microbiol 1999;37:14-17.
84. Dowell J, Pitkethly M, Bain J, Martin S. A randomised controlled trial of delayed antibiotic prescribing as a strategy for managing uncomplicated respiratory tract infection in primary care. Br J Gen Pract 2001;51(464): 200-205.
85. Dowell SF, Garman RL, Liu G, Levine OS, Yang YH. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001;32:824-825.
86. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001;33:492-503.
87. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa (January). The Annals of Pharmacotherapy 2004;aph.
88. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-824.
89. Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004;20:555-563.
90. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37: 752-760.
91. Edelstein PH, Meyer RD, Finegold SM. Laboratory diagnosis of Legionnaires' disease. Am Rev Respir Dis 1980;121:317-327.
92. Einarsson S, Kristjansson M, Kristinsson KG, Kjartansson G, Jonsson S. Pneumonia caused by penicillin-non-susceptible and penicillin-susceptible pneumococci in adults: a case-control study. Scand J Infect Dis 1998;30:253-256.
93. El Solh AA, Aquilina AT, Gunen H, Ramadan F. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004;52:224-229.
94. El Solh AA, Pietrantoni C, Bhat A, et al. Microbiology of severe aspiration pneumonia in institutionalized elderly. Am J Respir Crit Care Med 2003;167:1650-1654.
95. El Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001;163(3 Pt 1):645-651.
96. Eller J, Ede A, Schaberg T, Niederman MS, Mauch H, Lode H. Infective exacerbations of chronic bronchitis: relation betwen bacteriologic etiology and lung function. Chest 1998;113:1542-1548.
97. Emerman CL, Dawson N, Speroff T, et al. Comparison of physician judgment and decision aids for ordering chest radiographs for pneumonia in outpatients. Ann Emerg Med 1991;20:1215-1219.
98. Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004;59:421-427.
99. Ewig S, Kleinfeld T, Bauer TT, Schäfer H, Göke N. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999;14:370-375.
100. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-1108.
101. Ewig S, Schäfer H. Lungenabszesse neu betrachtet. Eine klinisch handlungsanleitende Klassifikation. Pneumologie 2001;55:195-201.
102. Ewig S, Schlochtermeier M, Göke N, Niederman MS. Applying sputum as a diagnostic tool in pneumonia: Limited yield, minimal impact on treatment decisions. Chest 2002;121:1486-1492.
103. Ewig S, Torres A, Marcos MA, et al. Factors associated with unknown aetiology in patients with community-acquired pneumonia. Eur Respir J 2002;20:1254-1262.
104. Ewig S, Tuschy P, Fätkenheuer G. Diagnostik und Therapie der Legionellen-Pneumonie. Pneumologie 2003;56:695-703.
105. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990;142:1004-1008.
106. Fahey T, Stocks N, Thomas T. Quantitative systematic review of randomised controlled trials comparing antibiotic with placebo for acute cough in adults. BMJ 1998;316(7135): 906-910.
107. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 1990;69:307-316.
108. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia. Ann Intern Med 1991;115:428-436.
109. Feikin DRJ, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90: 223-229.
110. Fein AM, Feinsilver SH, Niederman MS, Fiel S, Pai PB. When pneumonia doesn't get better. Clin Chest Med 1987;8:529-541.
111. Feinsilver SH, Fein AM, Niederman MS, Schultz DE, Faegenburg DH. Utility of fiberoptic bronchoscopy in non-resolving pneumonia. Chest 1990;98:1322-1326.
112. Feinsilver SH, Fein AM, Teitcher J. A practical approach to nonresolving pneumonia. Semin Respir Infect 1992;7:289-293.
113. Feldman C, Ross S, Goolam Mahomed A, Omar J, Smith C. The aetiology of severe community-acquired pneumonia and its impact on intial, empiric, antimicrobial treatment. Respir Med 1995;89:187-192.
114. Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. Arch Intern Med 2003;163:1718-1726.
115. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50 Suppl S1:25-37.
116. Fernandez-Sabe N, Carratala J, Dorca J, et al. Efficacy and safety of sequential amoxicillin-clavulanate in the treatment of anaerobic lung infections. Eur J Clin Microbiol Infect Dis 2003;22:185-187.
117. File TM, Jr., Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-1972.
118. Finch R, Schurmann D, Collins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002;46:1746-1754.
119. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. Drugs 1998;55:31-45.
120. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
121. Fine MJ, Hanusa BH, Lave JR, et al. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia. J Gen Intern Med 1995;10:359-368.
122. Fine MJ, Singer DE, Hanusa BH, Lave JR, Kapoor WN. Validation of a pneumonia prognostic index using the MedisGroups Comparative Hospital Database. Am J Med 1993;94:153-159.
123. Fine MJ, Smith DN, Singer DE. Hospitalization decision in patients with community-acquired pneumonia: a prospective cohort study. Am J Med 1990;89:713-721.
124. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994;154:2666-2677.
125. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996;275:134-141.
126. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999;159:970-980.
127. Fink MP, Snydman DR, Niederman MS, et al. Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. J Antimicrob Chemother 1994;38: 547-557.
128. Finkelstein MS, Petkun WM, Freedman ML, Antopol SC. Pneumococcal bacteremia in adults: age-dependent differences in presentation and in outcome. J Am Geriatr Soc 1983;31:19-27.
129. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31: 613-615.
130. Formica N, Yates M, Beers M, et al. The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires' disease. Epidemiol Infect 2001;127:275-280.
131. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002;24:1292-1308.
132. Franquet T. Imaging of pneumonia: trends and algorithms. Eur Respir J 2001;18:196-208.
133. Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977;297: 1189-1197.
134. Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive Care Med 2002;28:686-691.
135. Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001;20:14-19.
136. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol 1977;6: 396-399.
137. Geddes A, Thaler M, Schonwald S, Harkonen M, Jacobs F, Nowotny I. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 1999;44:799-810.
138. Gennis P, Gallagher J, Falvo C, Baker S, Than W. Clinical criteria for the detection of pneumonia in adults: guidelines for ordering chest roentgenograms in the emergency department. J Emerg Med 1989;7:263-268.
139. Gikas A, Kofteridis DP, Manios A, Pediaditis J, Tselentis Y. Newer Macrolides as Empiric Treatment for Acute Q Fever Infection. Antimicrob Agents Chemother 2001;45:3644-3646.
140. Gleason PP, Kapoor WN, Stone RA, et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997;278: 32-39.
141. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-2572.
142. Gonzales R, Steiner JF, Lum A, Barrett PH, Jr. Decreasing antibiotic use in ambulatory practice: impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999;281: 1512-1519.
143. Gonzales R, Steiner JF, Sande MA. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997;278:901-904.
144. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999;29:797-800.
145. Gordon JJ, Kauffman CA. Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin. Am J Med 1990;89: 383-384.
146. Gotfried MH, Dattani D, Riffer E, et al. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia. Clin Ther 2002;24:736-751.
147. Govaert TM, Sprenger MJ, Dinant GJ, Aretz K, Masurel N, Knottnerus JA. Immune response to influenza vaccination of elderly people. A randomized double-blind placebo-controlled trial. Vaccine 1994;12:1185-1189.
148. Grimm H, Funke G. Bedeutung der antibakteriellen Eigenaktivität von Sulbactam und Tazobactam für die Empfindlichkeitsprüfung von Inhibitor-geschützten Penicillinen. Chemother J 2004;13:238-241.
149. Groenewegen KH, Schols AMWJ, Wouters EFM. Mortality and Mortality-Related Factors After Hospitalization for Acute Exacerbation of COPD. Chest 2003;124:459-467.
150. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 1995;123:518-527.
151. Groth JJ. A pahrmacoeconomic study: clarithromycin in bronchitis and pneumonia. Klinikarzt 1998;4:22-24.
152. Gudiol F, Manresa F, Pallares R, et al. Clindamycin vs penicillin for anaerobic lung infections. High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus. Arch Intern Med 1990;150:2525-2529.
153. Guerrero C, Toldos CM, Yague G, Ramirez C, Rodriguez T, Segovia M. Comparison of diagnostic sensitivities of three assays (Bartels enzyme immunoassay [EIA], Biotest EIA, and Binax NOW immunochromatographic test) for detection of Legionella pneumophila serogroup 1 antigen in urine. J Clin Microbiol 2004;42:467-468.
154. Gutierrez F, Masia M, Rodriguez JC, et al. Evaluation of the Immunochromatographic Binax NOW Assay for Detection of Streptococcus pneumoniae Urinary Antigen in a Prospective Study of Community-Acquired Pneumonia in Spain. Clin Infect Dis 2003;36:286-292.
155. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection 2002;30:378-386.
156. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002;162:1278-1284.
157. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279: 1452-1457.
158. Halm EA, Teirstein AS. Clinical practice. Management of community-acquired pneumonia. N Engl J Med 2002;347:2039-2045.
159. Hammer DL, Aranda CP, Galati V, Adams FV. Massive intrabronchial aspiration of contents of pulmonary abscess after fiberoptic bronchoscopy. Chest 1978;74:306-307.
160. Hammond JM, Potgieter PD, Hanslo D, Scott H, Roditi D. The etiology and antimicrobial susceptibility patterns of microorganisms in acute community-acquired lung abscess. Chest 1995;108:937-941.
161. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997;337:874-880.
162. Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996;15:286-290.
163. Heckerling PS, Tape TG, Wigton RS, et al. Clinical prediction rule for pulmonary infiltrates. Ann Intern Med 1990;113:664-670.
164. Heckerling PS. The need for chest roentgenograms in adults with acute respiratory illness. Clinical predictors. Arch Intern Med 1986;146:1321-1324.
165. Hedlund JU, Kalin ME, Ortqvist AB, Henrichsen J. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994;154:1961-1965.
166. Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. J Clin Microbiol 2003;41:838-840.
167. Helbig JH, Uldum SA, Luck PC, Harrison TG. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol 2001;50:509-516.
168. Henriques B, Kalin M, Ortqvist A, et al. Molecular epidemiology of Streptococcus pneumoniae causing invasive disease in 5 countries. J Infect Dis 2000;182:833-839.
169. Hilf M, Yu VL, Sharp JT, Zuravleff JJ, Korvik JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989;87:540-546.
170. Hoeffken G, Meyer HP, Winter J, Verhoef L. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-564.
171. Höffken G, Steinhoff D, Lode H, et al. Ätiologie von ambulant erworbenen Pneumonien bei älteren Menschen. Chemotherapie J 1995;4:13-19.
172. Hook EW, III, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983;249:1055-1057.
173. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001;119:1420-1426.
174. Huber SL, Wood JS, Weston JS, Lomaestro BM, Timm EG. Antibiotic therapy in community-acquired pneumonia and the role of the hospital pharmacist. Am J Man Care 1999;5:S555-S569.
175. Hueston WJ, Mainous AG, Brauer N, Mercuri J. Evaluation and treatment of respiratory infections: does managed care make a difference? J Fam Pract 1997;44:572-577.
176. Ieven M, Goossens H. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Clin Microbiol Rev 1997;10:242-256.
177. Ieven M, Ursi D, Van Bever H, Quint W, Niesters HG, Goossens H. Detection of Mycoplasma pneumoniae by two polymerase chain reactions and role of M. pneumoniae in acute respiratory tract infections in pediatric patients. J Infect Dis 1996;173:1445-1452.
178. Ishida T, Hashimoto T, Arita M, Tojo Y, Tachibana H, Jinnai M. A 3-Year prospective study of a urinary antigen-detection for Streptoccus pneumoniae in community acquired pneumonia: utility and clinical impact on the reported etiology. J Infect Chemother 2004;10:359-363.
179. Jäcker A. Was sparen Generika wirklich? - Eine Analyse aus volkswirtschaftlicher Perspektive. Ges Pol 2004;2004:1-4.
180. Jackson LA, Benson P, Sneller VP, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281: 243-248.
181. Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52: 229-246.
182. Jimenez P, Saldias F, Meneses M, Silva ME, Wilson MG, Otth L. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia. Comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993;103: 1023-1027.
183. Johnson AP, Sheppard CL, Harnett SJ, et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 2003;52:953-960.
184. Johnson DM, Sader HS, Fritsche TR, Biedenbach DJ, Jones RN. Susceptibility trends of haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003;47: 373-376.
185. Jokinen C, Heiskanen L, Juvonen H, et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis 2001;32:1141-1154.
186. Jorgensen AF, Coolidge J, Pedersen PA, Petersen KP, Waldorff S, Widding E. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992;10:7-11.
187. Josephson MA, Agger WA, Bennett CL, Ullman M, Arnow PM. Performance measurement in pneumonia care: beyond report cards. Mayo Clin Proc 1998;73:5-9.
188. Kahn FW, Jones JH. Analysis of bronchoalveolar lavage specimens from immunocompromized patients with a protocol applicable in the microbiology laboratory. J Clin Microbiol 1988;26:1150-1155.
189. Kallings I, Nordstrom K. The pattern of immunoglobulins with special reference to IgM in Legionnaires' disease patients during a 2 year follow-up period. Zentralbl Bakteriol Mikrobiol Hyg [A] 1983;255:27-32.
190. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002;165:766-772.
191. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing rutual have clinical significance? Ann Intern Med 2002;136:817-825.
192. Karalus NC, Cursons RT, Leng RA, et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991;46:413-418.
193. Kashuba AD, Ballow CH. Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapy. Diagn Microbiol Infect Dis 1996;24:129-139.
194. Kays MB, Wack MF, Smith DW, Denys GA. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis 2002;43:163-165.
195. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000;31:1008-1011.
196. Kessler HH, Reinthaler FF, Pschaid A, et al. Rapid detection of Legionella species in bronchoalveolar lavage fluids with the EnviroAmp Legionella PCR amplification and detection kit. J Clin Microbiol 1993;31: 3325-3328.
197. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:158-164.
198. Kikuchi R, Watabe N, Konno T, Mishina N, Sekizawa K, Sasaki H. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994;150:251-253.
199. Kirtland SH, Winterbauer RH. Slowly resolving, chronic, and recurrent pneumonia. Clin Chest Med 1991;12:303-318.
200. Klein JS, Schultz S, Heffner JE. Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax. AJR Am J Roentgenol 1995;164:581-588.
201. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995;21: 616-620.
202. Kresken M, Hafner D, Schmitz FJ, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie aus dem Jahre 2001. 2003. Antiinfectives Intelligence, Bonn.
203. Kuru T, Lyons JP3. Nonresolving or slowly resolving pneumonia. Clin Chest Med 1999;20:623-651.
204. Lemmen SW, Hafner H, Kotterik S, Lutticken R, Topper R. Influence of an infectious disease service on antibiotic prescription behavior and selection of multiresistant pathogens. Infection 2000;28:384-387.
205. Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987;25:758-762.
206. Leophonte P, Veyssier P. [Levofloxacin in the treatment of community-acquired pneumococcal pneumonia]. Presse Med 1999;28: 1975-1979.
207. Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995;21:24-31.
208. Leroy O, Vandenbussche C, Coffinier C, et al. Community-acquired aspiration pneumonia in intensive care units. Epidemiological and prognosis data. Am J Respir Crit Care Med 1997;156:1922-1929.
209. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. Ann Intern Med 1983;98:466-471.
210. Lieberman D, Lieberman D, Shmarkov O, et al. Serological evidence of Legionella species infection in acute exacerbation of COPD. Eur Respir J 2002;19:392-397.
211. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996;51:179-184.
212. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000;55:219-223.
213. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001;56:296-301.
214. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001;18:362-368.
215. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377.
216. Lode H, Eller J, Linnhoff A, Ioanas M, the Evaluation of Therapy-Free Interval in COPD Patients Study Group. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. European Respiratory Journal 2004;24:947-953.
217. Lode H, Magyar P, Muir JF, Loos U, Kleutgens K. Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia. Clin Microbiol Infect 2004;10: 512-520.
218. Loeb M, McGeer A, McArthur M, Walter S, Simor AE. Risk factors for pneumonia and other lower respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999;159:2058-2064.
219. Loens K, Ieven M, Ursi D, et al. Detection of Mycoplasma pneumoniae by real-time nucleic acid sequence-based amplification. J Clin Microbiol 2003;41:4448-4450.
220. Loens K, Ursi D, Goossens H, Ieven M. Molecular diagnosis of Mycoplasma pneumoniae respiratory tract infections. J Clin Microbiol 2003;41:4915-4923.
221. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-564.
222. Lopez AD, Murray CC. The global burden of disease, 1990-2020. Nat Med 1998;4:1241-1243.
223. Lorenz W, Ollenschläger G. Das Leitlinien-Manual. Z Arztl Fortbild Qualitatssich 2001;95(Suppl 1):1-84.
224. Lück PC, Lobeck G, Stenzel G, Conzendorf C, Helbig JH. [Legionella pneumonia after travel to Mediterranean countries]. Z Arztl Fortbild (Jena) 1994;88(5-6):433-436.
225. Macfarlane J, Holmes W, Gard P, Thornhill D, Macfarlane R, Hubbard R. Reducing antibiotic use for acute bronchitis in primary care: blinded, randomised controlled trial of patient information leaflet. BMJ 2002;324(7329):91-94.
226. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adults lower-respiratory- tract infection in the community. Lancet 1993;341:511-514.
227. Macfarlane JT, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001;56: 109-114.
228. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37: 1405-1433.
229. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000;31: 385-421.
230. Mansel JK, Rosenow EC, III, Smith TF, Martin JW, Jr. Mycoplasma pneumoniae pneumonia. Chest 1989;95:639-646.
231. Mansharamani N, Balachandran D, Delaney D, Zibrak JD, Silvestri RC, Koziel H. Lung abscess in adults: clinical comparison of immunocompromised to non-immunocompromised patients. Respir Med 2002;96:178-185.
232. Mansharamani NG, Koziel H. Chronic lung sepsis: lung abscess, bronchiectasis, and empyema. Curr Opin Pulm Med 2003;9:181-185.
233. Marcos MA, Jimenez de Anta MT, de la Bellacasa JP, et al. Rapid urinary antigen test for diagnosis of pneumococcal community-acquired pneumonia in adults. Eur Respir J 2003;21:209-214.
234. Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001;344: 665-671.
235. Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000;15:85-90.
236. Marrie T. Normal resolution of community-acquired pneumonia. Semin Respir Infect 1992;7:289-293.
237. Marrie TJ, Durant H, Yates L. Community acquired pneumonia requiring hospitalisation: 5-year prospective study. Rev Infec Dis 1989;11:586-599.
238. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-755.
239. Marrie TJ. Q fever pneumonia. Current Opinion in Infectious Diseases 2004;17:137-142.
240. Marston BJ, Plouffe JF, File TM, Jr., et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997;157:1709-1718.
241. Martinez JA, Horcajada JP, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-395.
242. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001;18:503-512.
243. Matthay RA, Arroliga AC. Resection of pulmonary metastases. Am Rev Respir Dis 1993;148(6 Pt 1):1691-1696.
244. Mauch H, Wagner J, Marklein G, et al. MIQ 7 Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik - Infektionen der tiefen Atemwege. Teil 1 ed. Urban und Schwarzenberg, 1999.
245. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084.
246. Melbye H, Dale K. Interobserver variability in the radiographic diagnosis of adult outpatient pneumonia. Acta Radiol 1992;33:79-81.
247. Melbye H, Straume B, Aasebo U, Dale K. Diagnosis of pneumonia in adults in general practice. Relative importance of typical symptoms and abnormal chest signs evaluated against a radiographic reference standard. Scand J Prim Health Care 1992;10:226-233.
248. Menendez R, Perpina M, Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003;18:103-111.
249. Metlay JP, Fine MJ, Schulz R, et al. Measuring symptomatic and functional recovery in patients with community-acquired pneumonia. J Gen Intern Med 1997;12:423-430.
250. Metlay JP, Kapoor WN, et al. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997;278:1440-1445.
251. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997;157:1453-1459.
252. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999;116:40-46.
253. Mittl RL, Jr., Schwab RJ, Duchin JS, Goin JE, Albeida SM, Miller WT. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994;149(3 Pt 1):630-635.
254. Mogulkoc N, Karakurt S, Isalska B, et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am J Respir Crit Care Med 1999;160:349-353.
255. Moine P, Vercken JB, Chevret S, Chastang C, Gajdos P. Severe community-acquired pneumonia. Etiology, epidemiology, and prognosis factors. Chest 1994;105:1487-1495.
256. Monforte R, Estruch R, Vidal J, Cervera R, Urbano-Marquez A. Delayed seroconversion in Legionnaire's disease. Lancet 1988;2(8609):513.
257. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections. J Infect Dis 1999;180:254-261.
258. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999;44 Suppl B:23-29.
259. Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam Pract 2000;1:1.
260. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805.
261. Mortensen EM, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002;162:1059-1064.
262. Mortensen EM, Kapoor WN, Chang CCH, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003;37:1617-1624.
263. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med 1998;105:319-330.
264. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107(1A):34S-43S.
265. Mundy L.M., Auwaerter PG, Oldach D, et al. Community-acquired pneumonia. Impact of immune status. Am J Respir Crit Care Med 1995;152:1309-1315.
266. Mundy LM, Leet TL, Darst K, Schnitzler MA, Dunagan WC. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003;124:883-889.
267. Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR Assay for Detection of Streptococcus pneumoniae in Respiratory and Nonrespiratory Samples from Adults with Community-Acquired Pneumonia. J Clin Microbiol 2003;41:63-66.
268. Murdoch DR, Laing RT, Cook JM. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003;37:153-154.
269. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001;39:3495-3498.
270. Murdoch DR. Nucleic acid amplification tests for the diagnosis of pneumonia. Clin Infect Dis 2003;36:1162-1170.
271. Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975;50:339-344.
272. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-631.
273. Musso D, Drancourt M, Osscini S, Raoult D. Sequence of quinolone resistance-determining region of gyrA gene for clinical isolates and for an in vitro-selected quinolone-resistant strain of Coxiella burnetii. Antimicrob Agents Chemother 1996;40:870-873.
274. Musso D, Raoult D. Serological cross-reactions between Coxiella burnetii and Legionella micdadei. Clin Diagn Lab Immunol 1997;4:208-212.
275. Mwandumba HC, Beeching NJ. Pyogenic lung infections: factors for predicting clinical outcome of lung abscess and thoracic empyema. Curr Opin Pulm Med 2000;6:234-239.
276. Nakagawa T, Sekizawa K, Arai H, Kikuchi R, Manabe K, Sasaki H. High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 1997;157:321-324.
277. Neill AM, Martin IR, Weir R, et al. Community-acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-1016.
278. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003;289:885-888.
279. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784.
280. Nichol KL, Wuorenma J, Von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-1776.
281. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355(9218):1845-1850.
282. Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis. A controlled study using tetracycline. Ann Intern Med 1982;97:18-21.
283. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the Management of Adults with Community-acquired Pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-1754.
284. Niederman MS. How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med 2002;28:1003-1005.
285. Nimmo GR, Playford EG. Community-acquired MRSA bacteraemia: four additional cases including one associated with severe pneumonia. Med J Aust 2003;178:245.
286. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis 1998;30:397-404.
287. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001;358:2020-2025.
288. Nowak D, Dietrich ES, Oberender P, et al. Krankheitskosten von COPD in Deutschland. Pneumologie 2004;58:837-844.
289. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. European Respiratory Journal 2004;23:832-840.
290. O'Hanley P, Rodondi L, Coleman R. Efficacy and cost-effectiveness of antibiotic monitoring at a Veterans Administration hospital. Chemotherapy 1991;37(Suppl. 3):22-25.
291. Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. J Clin Epidemiol 1996;49:963-967.
292. Okimoto N, Kurihara T, Honda N, et al. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly. J Infect Chemother 2003;9:183-186.
293. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik EF, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92:1032-1039.
294. Oostenbrink J, Buijs-Van der Woude T, van Agthoven M, Koopmanschap M, Rutten F. Unit costs of inpatient hospital days. Pharmacoeconomics 2003;21:263-271.
295. Oosterheert JJ, Bonten MJM, Hak E, Schneider MME, Hoepelman IM. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 2003;52:555-563.
296. Ortiz-Ruiz G, Caballero-Lopez J, Friedland IR, Woods GL, Carides A, Protocol 018 Ertapenem Community-Acquired Pneumonia Study Group. A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults. Clin Infect Dis 2002;34:1076-1083.
297. Ortiz-Ruiz G, Vetter N, Isaacs R, Carides A, Woods GL, Friedland I. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies. J Antimicrob Chemother 2004;53 Suppl 2:ii59-ii66.
298. Ortqvist A, Hedlund J, Grillner L, et al. Aetiology, outcome and prognostic factors in patients with community acquired pneumonia requiring hospitalisation. Eur Respir J 1990;3:1105-1113.
299. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C. Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group. Chest 1996;110:1499-1506.
300. Pachon J, Prados MD, Capote F, Cuello JA, Garnacho J, Verano A. Severe community-acquired pneumonia. Etiology, prognosis, and treatment. Am Rev Respir Dis 1990;142: 369-373.
301. Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002;122:1271-1279.
302. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-480.
303. Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003;163: 1180-1186.
304. Paul M, Benuri-Silbiger I, Scares-Weiser K, Leibovici L. β-lactam monotherapy versus β-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328(7441):668-0.
305. Pereira Gomes JC, Pedreira JW, Jr., Araujo EM, et al. Impact of BAL in the management of pneumonia with treatment failure: positivity of BAL culture under antibiotic therapy. Chest 2000;118:1739-1746.
306. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-195.
307. Petitpretz P, Chidiac C, Soriano F, Garau J, Stevenson K, Rouffiac E. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin- clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002;20:119-129.
308. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000;44:1796-1802.
309. Plouffe JF, File TM, Jr., Breiman RF, et al. Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin Infect Dis 1995;20: 1286-1291.
310. Ponka A, Ponka T, Sarna S, Penttinen K. Questionable specificity of lipid antigen in the Mycoplasma pneumoniae complement fixation test in patients with extrapulmonary manifestations. J Infect 1981;3:332-338.
311. Porta G, Rodriguez-Carballeira M, Gomez L, et al. Thoracic infection caused by Streptococcus milleri. Eur Respir J 1998;12:357-362.
312. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995;155: 1273-1276.
313. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-2454.
314. Raoult D, Torres H, Drancourt M. Shell-vial assay: evaluation of a new technique for determining antibiotic susceptibility, tested in 13 isolates of Coxiella burnetii. Antimicrob Agents Chemother 1991;35:2070-2077.
315. Reinert RR, Al Lahham A, Lutticken R, Boos M, Schmilz FJ. Characterization of clinical Streptococcus pneumoniae strains from Germany with decreased susceptibility to fluoroquinolones. J Antimicrob Chemother 2002;49:1015-1018.
316. Reinert RR, Al-Lahham A, Lemperle M, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002;49:61-68.
317. Reinert RR, Rodloff AC, Halle E, et al. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Germany and activity of the Ketolide Telitnromycin: results from the PROTEKT surveillance study (1999-2000). Chemotherapy 2004;50:143-151.
318. Reischl U, Lehn N, Simnacher U, Marre R, Essig A. Rapid and standardized detection of Chlamydia pneumoniae using LightCycler real-time fluorescence PCR. Eur J Clin Microbiol Infect Dis 2003;22:54-57.
319. Reischl U, Linde HJ, Lehn N, Landt O, Barratt K, Wellinghausen N. Direct detection and differentiation of Legionella spp. and Legionella pneumophila in clinical specimens by dual-color real-time PCR and melting curve analysis. J Clin Microbiol 2002;40:3814-3817.
320. Rello J, Ausina V, Ricart M, Castella J, Prats G. Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993;104:1230-1235.
321. Rello J, Bodi M, Mariscal D, et al. Microbiological Testing and Outcome of Patients With Severe Community-Acquired Pneumonia. Chest 2003;123:174-180.
322. Rello J, Catalan M, Diaz E, Bodi M, Alvarez B. Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002;28: 1030-1035.
323. Rhew DC, Hackner D, Henderson L, Ellrodt AG, Weingarten SR. The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy. Chest 1998;113:142-146.
324. Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001;161:722-727.
325. Richerson MA, Ambrose PG, Quintiliani R, Bui KQ, Nightingale CH. Pharmacoeconomic evaluation of alternative antibiotic regimens in hospitalized patients with community-acquired pneumonia. Infect Dis Clin Pract 1998;7:227-233.
326. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly, clinical and nutritional aspects. Am J Respir Crit Care Med 1997;156:1908-1914.
327. Riquelme R, Torres A, El-Ebiary M, et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996;154:1450-1455.
328. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-1377.
329. Robertson L, Caley JP, Moore J. Importance of Staphylococcus aureus in pneumonia in the 1957 epidemic of influenza A. Lancet 1958;2(7040):233-236.
330. Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalization - a case-control study. Thorax 2003;58:37-42.
331. Roos-Van Eijndhoven DG, Cools HJ, Westendorp RG, Cate-Hoek AJ, Knook DL, Remarque EJ. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J Med Virol 2001;63:293-298.
332. Roson B, Carratala J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001;33: 158-165.
333. Roson B, Carratala J, Verdaguer R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach
334. Ross JJ, Worthington MG, Gorbach SL. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;347:65-67.
335. Rubinstein E, Cammarata S, Oliphant T, Wunderink RG, Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32: 402-412.
336. Ruf B, Schurmann D, Horbach I, Fehrenbach FJ, Pohle HD. Prevalence and diagnosis of Legionella pneumonia: a 3-year prospective study with emphasis on application of urinary antigen detection. J Infect Dis 1990;162: 1341-1348.
337. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia in hospitalized patients: Impact of age, comorbidity and severity. Am J Respir Crit Care Med 1999;160:397-405.
338. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia in hospitalized patients: Impact of age, comorbidity and severity. American Journal of Respiratory and Critical Care Medicine 159[3], A559. 1999.
339. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999;160:923-929.
340. Ruuskanen O, Nohynek H, Ziegler T, et al. Pneumonia in childhood: etiology and response to antimicrobial therapy. Eur J Clin Microbiol Infect Dis 1992;11:217-223.
341. Sachs AP, Koeter GH, Groenier KH, van der Waaij D, Schiphuis J, Meyboom-de Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995;50:758-763.
342. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4:519-527.
343. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV, Thornsberry C. Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. J Antimicrob Chemother 2000;45:457-466.
344. Salvarezza CR, Mingrone H, Fachinelli H, Kijanczuk S. Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia. J Antimicrob Chemother 1998;41 Suppl B:75-80.
345. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800.
346. Sanchez F, Mensa J, Martinez JA, et al. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? Clin Infect Dis 2003;36:1239-1245.
347. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-348.
348. Schaberg T, Dalhoff K, Ewig S, Lorenz J, Wilkens H. Empfehlungen zur Therapie der ambulant erworbenen Pneumonie. Deutsche Gesellschaft für Pneumologie. Pneumologie 1998;52:450-462.
349. Schädlich PK, Huppertz E, Brecht JG. Levofloxacin versus relevant alternatives in inpatient treatment of community-acquired pneumonia: results of a german economic evaluation. (Abstract T105). Antiinfect Drugs Chemother 1998;16(Suppl. 1):62.
350. Scheid WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
351. Schilling RS, Hughes JP, Dingwall-Fordyce I. Disagreement between observers in an epidemiological study of respiratory disease. Br Med J 1955;4905:65-68.
352. Schonhofer B, Kohler D. Prevalence of deep-vein thrombosis of the leg in patients with acute exacerbation of chronic obstructive pulmonary disease. Respiration 1998;65: 173-177.
353. Schonwald S, Kuzman I, Oreskovic K, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome-a randomized study. Infection 1999;27:198-202.
354. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001;286:49-56.
355. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory Viruses, Symptoms, and Inflammatory Markers in Acute Exacerbations and Stable Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001;164:1618-1623.
356. Sethi S, Evans N, Grant BJ, Murphy TF. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-471.
357. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: A prospective, randomized, double-blind study. Am J Ther 1999;6:217-222.
358. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110: 965-971.
359. Smith CB, Golden CA, Kanner RE, Renzetti AD, Jr. Association of viral and Mycoplasma pneumoniae infections with acute respiratory illness in patients with chronic obstructive pulmonary diseases. Am Rev Respir Dis 1980;121:225-232.
360. Smith MD, Derrington P, Evans R, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003;41:2810-2813.
361. Smith RP, Lipworth BJ, Cree IA, Spiers EM, Winter JH. C-reactive protein. A clinical marker in community-acquired pneumonia. Chest 1995;107:1028-1031.
362. Soler N, Torres A, Celis R, et al. Bronchial microbial pattern in non-severe exacerbations of chronic obstructive pulmonary disease (COPD): A bronchoscopic study. Eur Respir J 16 (Supp 31), 332s. 2000.
363. Sopena N, Sabria M, Pedro-Botet ML, et al. Prospective study of community-acquired pneumonia of bacterial etiology in adults. Eur J Clin Microbiol Infect Dis 1999;18: 852-858.
364. Spiteri MA, Cook DG, Clarke SW. Reliability of eliciting physical signs in examination of the chest. Lancet 1988;1(8590):873-875.
365. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999;159:2576-2580.
366. Standing Medical Advisory Committee. The Path of Least Resistance. 1998. Department of Health, London, UK.
367. Statistisches Bundesamt. Diagnosedaten der Krankenhauspatientinnen und -patienten 2002. 6.2 ed. 2004.
368. Statistisches Bundesamt. Todesursachen in Deutschland. 4 ed. 2004.
369. Stelianides S, Golmard JL, Carbon C, Fantin B. Influence of socioeconomic status on features and outcome of community-acquired pneumonia. Eur J Clin Microbiol Infe
370. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481-1490.
371. STIKO. Empfehlungen der ständigen Impfkommission (STIKO) am Robert-Koch Institut/Stand Juli 2002. Epidemiol Bull 2002;28:227-242.
372. Stockley
373. Suwangool P, Moola-Or P, Waiwatana A, Sitthi-Amorn C, Israsena S, Hanvanich M. Effect of a selective restriction policy on antibiotic expenditure and use: an institutional model. J Med Assoc Thai 1991;74:272-275.
374. Syrjala H, Broas M, Suramo I, Ojala A, Lahde S. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998;27:358-363.
375. Tablan OC, Anderson LJ, Besser R, Bridges C, Hajjeh R. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep 2004;53(RR-3):1-36.
376. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2004;39:641-648.
377. Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis 1996;23:671-682.
378. Tellier G, Niederman MS, Nusrat R, Patel M, Lavin B. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-523.
379. Templeton KE, Scheltinga SA, Graffelman AW, et al. Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-based amplification, conventional PCR, and serology for diagnosis of Mycoplasma pneumoniae. J Clin Microbiol 2003;41:4366-4371.
380. Templeton KE, Scheltinga SA, Sillekens P, et al. Development and clinical evaluation of an internally controlled, single-tube multiplex real-time PCR assay for detection of Legionella pneumophila and other Legionella species. J Clin Microbiol 2003;41:4016-4021.
381. The British Thoracic Society Research Committee and The Public Health Laboratory Service. The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992;86:7-13.
382. Theerthakarai R, El Halees W, Ismail M, Solis RA, Khan MA. Nonvalue of the Initial Microbiological Studies in the Management of Nonsevere Community-Acquired Pneumonia. Chest 2001;119:181-184.
383. Tomiyama N, Muller NL, Johkoh T, et al. Acute parenchymal lung disease in immunocompetent patients: diagnostic accuracy of high-resolution CT. AJR Am J Roentgenol 2000;174:1745-1750.
384. Tompkins LS, Schachter J, Boman J, et al. Collaborative multidisciplinary workshop report: detection, culture, serology, and antimicrobial susceptibility testing of Chlamydia pneumoniae. J Infect Dis 2000;181 Suppl 3: S460-S461.
385. Torres A, Bauer TT, Leon C, et al. Treatment of severe nosocomial pneumonia requiring mechanical ventilation: A prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000;55:1033-1039.
386. Torres A, Serra BJ, Ferrer A, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-318.
387. Toubes E, Singh K, Yin D, et al. Risk factors for antibiotic-resistant infection and treatment outcomes among hospitalized patients transferred from long-term care facilities: does antimicrobial choice make a difference? Clin Infect Dis 2003;36:724-730.
388. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016-1024.
389. Trosini-Desert V, Germaud P, Dautzenberg B. Tobacco smoke and risk of bacterial infection. Rev Mal Respir 2004;21(3 Pt 1): 539-547.
390. Ursi D, Dirven K, Loens K, Ieven M, Goossens H. Detection of Mycoplasma pneumoniae in respiratory samples by real-time PCR using an inhibition control. J Microbiol Methods 2003;55:149-153.
391. Van den BP, Vondra V, Vogel F, Schlaeffer F, Staley H, Holmes C. Sequential therapy with cefuroxime followed by cefuroxime axetil in community-acquired pneumonia. Chest 1997;112:406-415.
392. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003;51:691-696.
393. vanSonnenberg E, D'Agostino HB, Casola G, Wittich GR, Varney RR, Harker C. Lung abscess: CT-guided drainage. Radiology 1991;178:347-351.
394. Vergis EN, Indorf A, File TM, Jr., et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000;160:1294-1300.
395. Vetter N, Cambronero-Hernandez E, et al. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia. Clin Ther 2002;24:1770-1785.
396. Wandstrat TL, Kaplan B. Pharmacoeconomic impact of factors affecting compliance of antibiotic regimens in the treatment of acute otitis media. Pediatr Infect Dis J 1997;16(Suppl. 2):S27-S29.
397. Wasserfallen JB, Erard V, Cometta A, Calandra T, Lamy O. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia. European Respiratory Journal 2004;24:644-648.
398. Waterer GW, Baselski VS, Wunderink RG. Legionella and community-acquired pneumonia: a review of current diagnostic tests from a clinician's viewpoint. Am J Med 2001;110:41-48.
399. Waterer GW, Kessler LA, Wunderink RG. Medium-Term Survival after Hospitalization with Community-Acquired Pneumonia. Am J Respir Crit Care Med 2004;169:910-914.
400. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-1842.
401. Waterer GW, Wunderink RG, Jones CB. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 2000;118:1839-1840.
402. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82.
403. Watkins-Riedel T, Stanek G, Daxboeck F. Comparison of SeroMP IgA with four other commercial assays for serodiagnosis of Mycoplasma pneumoniae pneumonia. Diagn Microbiol Infect Dis 2001;40(1-2):21-25.
404. Watson L, Wilson BJ, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002;20(17-18):2166-2173.
405. Weir SC, Fischer SH, Stock F, Gill VJ. Detection of Legionella by PCR in respiratory specimens using a commercially available kit. Am J Clin Pathol 1998;110:295-300.
406. Weite T, Marre R, Suttorp N. Das Kompetenznetzwerk Ambulant erworbene Pneumonie (CAPNETZ) Ein erster Zwischenbericht. Internist (Berl) 2004.
407. Welti M, Jaton K, Altwegg M, Sahli R, Wenger A, Bille J. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn Microbiol Infect Dis 2003;45:85-95.
408. Wever PC, Yzerman EP, Kuijper EJ, Speelman P, Dankert J. Rapid diagnosis of Legionnaires' disease using an immunochromatographic assay for Legionella pneumophila serogroup 1 antigen in urine during an outbreak in the Netherlands. J Clin Microbiol 2000;38:2738-2739.
409. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway Bacterial Load and FEV1 Decline in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2003;167:1090.
410. Williams D, Perri M, Zervos MJ. Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia. Eur J Clin Microbiol Infect Dis 1994;13:293-298.
411. Wilson R, Allegra L, Huchon G, et al. Short-term and Long-term Outcomes of Moxifloxacin Compared to Standard Antibiotic Treatment in Acute Exacerbations of Chronic Bronchitis. Chest 2004;125:953-964.
412. Wilson R, Schentag JJ, Ball P, Mandell L. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin Ther 2002;24:639-652.
413. Wipf JE, Lipsky BA, Hirschmann JV, et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999;159:1082-1087.
414. Witte W, Cuny C, Strommenger B, Braulke C, Heuck D. Emergence of a new community acquired MRSA strain in Germany. Euro Surveill 2004;9:1-2.
415. Wong CA, Donald F, Macfarlane JT. Streptococcus milleri pulmonary disease: a review and clinical description of 25 patients. Thorax 1995;50:1093-1096.
416. Woodhead M, Ortqvist A. Pulmonary infections: what to do when it's a bug that you do not know. Eur Respir J 2003;21:201.
417. Woodhead M. Pneumonia in the elderly. J Antimicrob Chemother 1994;34 Suppl A:85-92.
418. Worth G, Buhl R, Cegla U, et al. Leitlinie der Deutschen Atemwegsliga und der Deutschen Gesellschaft für Pneumologie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD). Pneumologie 2003;56:704-738.
419. Wunderink RG, Waterer GW. Appropriate microbiological testing in community-acquired pneumonia. Chest 2001;119:5-7.
420. Yang PC, Luh KT, Lee YC, et al. Lung abscesses: US examination and US-guided transthoracic aspiration. Radiology 1991;180:171-175.
421. Young M, Marrie TJ. Interobserver variability in the interpretation of chest roentgenograms of patients with possible pneumonia. Arch Intern Med 1994;154:2729-2732.
422. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-237.
423. YU VL, Greenberg RN, Zadeikis N, et al. Levofloxacin Efficacy in the Treatment of Community-Acquired Legionellosis. Chest 2004;125:2135-2139.
424. Yzerman EP, Den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peelers M. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J Clin Microbiol 2002;40:3232-3236.
425. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res 2003;31: 157-169.
426. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002;62:13-59.
427. Zuck P, Rio Y, Ichou F. Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia. J Antimicrob Chemother 1990;26 Suppl E:71-77.
428. Zuravleff JJ, Yu VL, Shonnard JW, Davis BK, Rihs JD. Diagnosis of Legionnaires' disease. An update of laboratory methods with new emphasis on isolation by culture. JAMA 1983;250:1981-1985.